NASDAQ:GERN - Geron Stock Price, Price Target & More

$4.09 +0.08 (+2.00 %)
(As of 04/24/2018 12:36 PM ET)
Previous Close$4.01
Today's Range$4.02 - $4.28
52-Week Range$1.74 - $6.68
Volume3.38 million shs
Average Volume6.19 million shs
Market Capitalization$608.88 million
P/E Ratio-22.61
Dividend YieldN/A
Beta2.26

About Geron (NASDAQ:GERN)

Geron logoGeron Corporation (Geron) is a biopharmaceutical company, which supports the clinical stage development of a telomerase inhibitor, Imetelstat, in hematologic myeloid malignancies by Janssen Biotech, Inc. (Janssen). The Company is engaged in the development of therapeutic products for oncology. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity. Janssen is engaged in the development of Imetelstat with two clinical trials, such as a Phase II trial in myelofibrosis (MF), referred to as IMbark, and a Phase II/III trial in myelodysplastic syndromes (MDS) referred to as IMerge. Imetelstat is a lipid conjugated 13-mer oligonucleotide that is designed to be complementary to and bind with high affinity to the RNA template of telomerase, thereby directly inhibiting telomerase activity.

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Debt-to-Equity RatioN/A
Current Ratio14.74%
Quick Ratio14.74%

Price-To-Earnings

Trailing P/E Ratio-22.61
Forward P/E Ratio409.00
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.07 million
Price / Sales614.07
Cash FlowN/A
Price / CashN/A
Book Value$0.65 per share
Price / Book6.29

Profitability

EPS (Most Recent Fiscal Year)($0.18)
Net Income$-27,910,000.00
Net Margins-2,621.22%
Return on Equity-25.25%
Return on Assets-23.38%

Miscellaneous

Employees18
Outstanding Shares160,650,000

How to Become a New Pot Stock Millionaire

Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Friday, March, 16th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by $0.01. The biopharmaceutical company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.41 million. Geron had a negative net margin of 2,621.22% and a negative return on equity of 25.25%. Geron's revenue for the quarter was up 103.2% compared to the same quarter last year. During the same quarter last year, the business earned ($0.05) EPS. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

4 analysts have issued 12-month price objectives for Geron's stock. Their forecasts range from $4.00 to $7.00. On average, they anticipate Geron's stock price to reach $5.50 in the next twelve months. View Analyst Ratings for Geron.

Are investors shorting Geron?

Geron saw a increase in short interest in March. As of March 29th, there was short interest totalling 44,086,309 shares, an increase of 19.1% from the March 15th total of 37,028,235 shares. Based on an average daily volume of 23,019,985 shares, the short-interest ratio is presently 1.9 days. Approximately 27.6% of the shares of the company are short sold.

Who are some of Geron's key competitors?

Who are Geron's key executives?

Geron's management team includes the folowing people:
  • Hoyoung Huh Ph.D., Independent Chairman of the Board (Age 48)
  • John A. Scarlett M.D., President, Chief Executive Officer, Director (Age 66)
  • Olivia K. Bloom, Chief Financial Officer, Executive Vice President - Finance, Treasurer (Age 46)
  • Stephen N. Rosenfield J.D., Executive Vice President, General Counsel and Corporate Secretary (Age 62)
  • Andrew J. Grethlein Ph.D., Executive Vice President - Development and Technical Operations (Age 50)
  • Melissa A. Kelly Behrs, Executive Vice President - Business Development and Portfolio and Alliance Management (Age 51)
  • Susan M. Molineaux Ph.D., Director (Age 63)
  • Daniel Mark Bradbury, Independent Director (Age 56)
  • Karin Eastham CPA, Independent Director (Age 67)
  • V. Bryan Lawlis Jr. Ph.D., Independent Director (Age 65)

Has Geron been receiving favorable news coverage?

News headlines about GERN stock have been trending somewhat negative on Tuesday, according to Accern Sentiment. The research firm identifies positive and negative press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Geron earned a news impact score of -0.01 on Accern's scale. They also gave headlines about the biopharmaceutical company an impact score of 43.99 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $4.07.

How big of a company is Geron?

Geron has a market capitalization of $608.88 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,910,000.00 in net income (profit) each year or ($0.18) on an earnings per share basis. Geron employs 18 workers across the globe.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]


MarketBeat Community Rating for Geron (GERN)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  237 (Vote Outperform)
Underperform Votes:  184 (Vote Underperform)
Total Votes:  421
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Geron (NASDAQ:GERN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Geron in the last 12 months. Their average twelve-month price target is $5.50, suggesting that the stock has a possible upside of 34.47%. The high price target for GERN is $7.00 and the low price target for GERN is $4.00. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.502.502.502.50
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.50$5.50$4.1667$4.1667
Price Target Upside: 34.47% upside29.41% upside96.54% upside45.18% upside

Geron (NASDAQ:GERN) Consensus Price Target History

Price Target History for Geron (NASDAQ:GERN)

Geron (NASDAQ:GERN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/19/2018Piper JaffrayReiterated RatingBuy$7.00HighView Rating Details
3/18/2018Stifel NicolausBoost Price TargetHold -> Hold$2.50 -> $4.00HighView Rating Details
11/3/2017Needham & Company LLCReiterated RatingHoldN/AView Rating Details
7/4/2017FBR & CoReiterated RatingBuyMediumView Rating Details
9/20/2016BTIG ResearchReiterated RatingNeutralN/AView Rating Details
(Data available from 4/24/2016 forward)

Earnings

Geron (NASDAQ:GERN) Earnings History and Estimates Chart

Earnings by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ:GERN) Earnings Estimates

Current Year EPS Consensus Estimate: $0.01 EPS
Next Year EPS Consensus Estimate: $-0.18 EPS

Geron (NASDAQ GERN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018        
3/16/2018Q4 2017($0.04)($0.05)$0.41 million$0.19 millionViewListenView Earnings Details
11/1/2017Q3 2017($0.05)($0.04)$0.40 million$0.16 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.05)($0.04)$0.38 million$0.17 millionViewN/AView Earnings Details
5/9/2017Q1 2017($0.05)($0.05)$0.27 million$0.54 millionViewN/AView Earnings Details
3/1/2017Q416($0.06)($0.05)$0.18 million$0.09 millionViewListenView Earnings Details
11/3/2016Q316($0.06)($0.02)$0.22 million$5.10 millionViewListenView Earnings Details
8/3/2016Q216($0.07)($0.05)$0.38 million$0.21 millionViewListenView Earnings Details
5/5/2016Q116($0.06)($0.06)$0.26 million$0.74 millionViewListenView Earnings Details
2/25/2016Q415($0.05)($0.05)$0.32 million$0.22 millionViewListenView Earnings Details
11/5/2015Q315$0.11$0.17$17.87 million$35.40 millionViewListenView Earnings Details
8/5/2015Q2 15($0.06)($0.05)$0.40 million$0.25 millionViewN/AView Earnings Details
4/30/2015Q1($0.06)($0.06)$0.32 million$0.54 millionViewN/AView Earnings Details
3/3/2015Q4$0.17($0.06)$35.35 million$0.18 millionViewListenView Earnings Details
11/5/2014Q314($0.06)($0.06)$0.28 million$0.16 millionViewN/AView Earnings Details
8/11/2014Q214($0.06)($0.06)$0.22 million$0.34 millionViewListenView Earnings Details
5/1/2014Q114($0.06)($0.06)$0.35 million$0.47 millionViewListenView Earnings Details
3/27/2014($0.06)($0.07)ViewN/AView Earnings Details
3/17/2014Q413($0.07)($0.07)$0.35 million$0.23 millionViewListenView Earnings Details
11/7/2013Q313($0.06)($0.06)$0.49 million$0.18 millionViewListenView Earnings Details
8/8/2013Q2 2013($0.07)($0.07)$0.50 million$0.11 millionViewListenView Earnings Details
4/25/2013Q1 2013($0.08)($0.09)$0.71 million$0.77 millionViewListenView Earnings Details
3/12/2013Q4 2012($0.14)($0.12)$0.50 million$0.69 millionViewListenView Earnings Details
10/30/2012Q312($0.14)($0.13)$0.38 million$0.6360 millionViewN/AView Earnings Details
7/31/2012($0.15)($0.14)ViewN/AView Earnings Details
5/2/2012($0.18)($0.15)ViewN/AView Earnings Details
3/7/2012Q4 2011($0.20)($0.22)ViewN/AView Earnings Details
11/3/2011($0.18)($0.16)ViewN/AView Earnings Details
7/28/2011($0.18)($0.17)ViewN/AView Earnings Details
4/27/2011($0.19)($0.20)ViewN/AView Earnings Details
2/24/2011($0.19)($0.39)ViewN/AView Earnings Details
10/28/2010Q3 2010($0.20)($0.19)ViewN/AView Earnings Details
7/29/2010Q2 2010($0.19)($0.18)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.20)($0.18)ViewN/AView Earnings Details
2/25/2010Q4 2009($0.17)($0.20)ViewN/AView Earnings Details
10/29/2009Q3 2009($0.21)($0.17)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.19)($0.23)ViewN/AView Earnings Details
4/29/2009Q1 2009($0.20)($0.20)ViewN/AView Earnings Details
2/26/2009Q4 2008($0.21)($0.22)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.20)($0.22)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.20)($0.17)ViewN/AView Earnings Details
4/29/2008Q1 2008($0.18)($0.18)ViewN/AView Earnings Details
2/27/2008Q4 2007($0.12)($0.22)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Geron (NASDAQ:GERN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Geron (NASDAQ GERN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.20%
Institutional Ownership Percentage: 36.89%
Insider Trading History for Geron (NASDAQ:GERN)
Institutional Ownership by Quarter for Geron (NASDAQ:GERN)

Geron (NASDAQ GERN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/29/2015Olivia Kyusuk BloomCFOSell2,380$3.84$9,139.20View SEC Filing  
3/18/2015Thomas HofstaetterDirectorSell70,000$4.10$287,000.00View SEC Filing  
5/29/2014Melissa Kelly BehrsEVPSell4,826$2.10$10,134.60View SEC Filing  
5/29/2014Olivia Kyusuk BloomCFOSell3,379$2.10$7,095.90View SEC Filing  
5/9/2014Daniel BradburyDirectorBuy142,776$1.75$249,858.00142,776View SEC Filing  
4/1/2014Melissa Kelly BehrsEVPSell12,310$2.13$26,220.30147,841View SEC Filing  
4/1/2014Olivia Kyusuk BloomCFOSell7,435$2.13$15,836.5585,347View SEC Filing  
4/1/2013John A ScarlettCEOBuy50,000$1.03$51,500.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Geron (NASDAQ GERN) News Headlines

Source:
DateHeadline
Geron (GERN) Stock Rating Lowered by BidaskClubGeron (GERN) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
Geron (GERN) Given "Buy" Rating at FBR & CoGeron (GERN) Given "Buy" Rating at FBR & Co
www.americanbankingnews.com - April 19 at 10:12 PM
Johnson & Johnson Reaffirms Gerons Imetelstat As Lead Oncology Pipeline DrugJohnson & Johnson Reaffirms Geron's Imetelstat As Lead Oncology Pipeline Drug
seekingalpha.com - April 19 at 5:40 PM
Geron (GERN) Downgraded to Hold at Zacks Investment ResearchGeron (GERN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 19 at 12:49 PM
Geron (GERN) Rating Increased to Buy at Zacks Investment ResearchGeron (GERN) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - April 18 at 12:50 PM
Why Geron Corporations Stock Is Heading Higher TodayWhy Geron Corporation's Stock Is Heading Higher Today
www.fool.com - April 18 at 8:16 AM
Geron Faces A Make-Or-Break Catalyst This WeekGeron Faces A Make-Or-Break Catalyst This Week
seekingalpha.com - April 17 at 5:54 PM
Why Geron Corporation's Stock Is Heading Higher TodayWhy Geron Corporation's Stock Is Heading Higher Today
finance.yahoo.com - April 17 at 5:54 PM
Why Geron Doesnt Pass Our ScreensWhy Geron Doesn't Pass Our Screens
seekingalpha.com - April 16 at 8:16 AM
Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report?Why Is Geron (GERN) Up 10.6% Since Its Last Earnings Report?
finance.yahoo.com - April 16 at 8:16 AM
Here's Why Geron Stock Surged More Than 90% in 6 MonthsHere's Why Geron Stock Surged More Than 90% in 6 Months
finance.yahoo.com - April 13 at 5:32 PM
Rounds Report: Geron Rallied While FDAs New Guidance Created Tailwinds For Individualized Medicine InnovatorsRounds Report: Geron Rallied While FDA's New Guidance Created Tailwinds For Individualized Medicine Innovators
seekingalpha.com - April 13 at 8:19 AM
Today’s Research Reports on Stocks to Watch: Geron Corp. and Rigel PharmaceuticalsToday’s Research Reports on Stocks to Watch: Geron Corp. and Rigel Pharmaceuticals
finance.yahoo.com - April 13 at 8:19 AM
Why Geron Corporation Stock Is on the Rise TodayWhy Geron Corporation Stock Is on the Rise Today
finance.yahoo.com - April 12 at 3:21 PM
Geron Co. (GERN) Short Interest UpdateGeron Co. (GERN) Short Interest Update
www.americanbankingnews.com - April 12 at 2:18 AM
 Brokerages Anticipate Geron Co. (GERN) to Announce -$0.04 EPS Brokerages Anticipate Geron Co. (GERN) to Announce -$0.04 EPS
www.americanbankingnews.com - April 12 at 1:13 AM
BioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 ApprovedBioSci Rounds Report: Regenxbio Surged, Geron Trading Reversed And Dexcom G6 Approved
seekingalpha.com - April 10 at 8:27 AM
Geron Corp.: Its Hard Enough To Get A Drug To Market Without The Questionable Bearish ArgumentsGeron Corp.: It's Hard Enough To Get A Drug To Market Without The Questionable Bearish Arguments
seekingalpha.com - April 10 at 8:27 AM
Geron Corp.: Its Hard Enough To Get A Drug To Market Without The Misinformed AttacksGeron Corp.: It's Hard Enough To Get A Drug To Market Without The Misinformed Attacks
seekingalpha.com - April 9 at 5:21 PM
Geron (GERN) Downgraded by Zacks Investment ResearchGeron (GERN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM
BioSci Rounds Report: Intercept Making A Comeback, Improving FDA Policy Can Help GeronBioSci Rounds Report: Intercept Making A Comeback, Improving FDA Policy Can Help Geron
seekingalpha.com - April 6 at 5:41 PM
Geron: The Better, The Worse And The UglierGeron: The Better, The Worse And The Uglier
seekingalpha.com - April 6 at 8:27 AM
BioSci Research On Geron (Part II): Evaluating The Hidden Value Of The Myelofibrosis FranchiseBioSci Research On Geron (Part II): Evaluating The Hidden Value Of The Myelofibrosis Franchise
seekingalpha.com - April 5 at 5:17 PM
GERON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Geron Corporation To Contact The FirmGERON INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Geron Corporation To Contact The Firm
finance.yahoo.com - April 5 at 5:17 PM
Your Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path ResultsYour Daily Pharma Scoop: Geron Update, Rigel Setback, Bio-Path Results
seekingalpha.com - April 4 at 8:21 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Geron CorporationSHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Geron Corporation
finance.yahoo.com - April 3 at 5:35 PM
Why Geron Corporation Stock Is Falling TodayWhy Geron Corporation Stock Is Falling Today
finance.yahoo.com - April 2 at 5:27 PM
Geron Co. (GERN) Receives Average Rating of "Hold" from AnalystsGeron Co. (GERN) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - April 1 at 1:54 AM
BidaskClub Downgrades Geron (GERN) to BuyBidaskClub Downgrades Geron (GERN) to Buy
www.americanbankingnews.com - March 30 at 1:06 PM
Heres Why Gerons Stock Is Cratering TodayHere's Why Geron's Stock Is Cratering Today
www.nasdaq.com - March 30 at 8:23 AM
IMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron CorporationIMPORTANT SHAREHOLDER ALERT: The Schall Law Firm Announces it is Investigating Claims Against Geron Corporation
finance.yahoo.com - March 29 at 5:30 PM
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Geron Corporation (GERN)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Geron Corporation (GERN)
finance.yahoo.com - March 28 at 5:18 PM
Here's Why Geron's Stock Is Cratering TodayHere's Why Geron's Stock Is Cratering Today
finance.yahoo.com - March 28 at 5:18 PM
EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Geron Corporation - GERNEQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Geron Corporation - GERN
finance.yahoo.com - March 28 at 5:18 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERNSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Geron Corporation - GERN
www.prnewswire.com - March 27 at 6:19 PM
Why Geron Corporation Stock Is Crashing TodayWhy Geron Corporation Stock Is Crashing Today
finance.yahoo.com - March 27 at 5:14 PM
Why Twitter, Overstock.com, and Geron Slumped TodayWhy Twitter, Overstock.com, and Geron Slumped Today
finance.yahoo.com - March 27 at 5:14 PM
Geron slips 7% premarket on bearish Feuerstein articleGeron slips 7% premarket on bearish Feuerstein article
seekingalpha.com - March 27 at 8:13 AM
Geron (GERN) Rating Increased to Hold at BidaskClubGeron (GERN) Rating Increased to Hold at BidaskClub
www.americanbankingnews.com - March 26 at 5:58 PM
Geron Co. (GERN) Expected to Announce Earnings of -$0.04 Per ShareGeron Co. (GERN) Expected to Announce Earnings of -$0.04 Per Share
www.americanbankingnews.com - March 26 at 3:24 AM
Why Geron Corp. Is Rallying 10% TodayWhy Geron Corp. Is Rallying 10% Today
finance.yahoo.com - March 23 at 5:42 PM
Is Geron Corporation Stock Still a Strong Buy?Is Geron Corporation Stock Still a Strong Buy?
finance.yahoo.com - March 22 at 5:36 PM
Exploring Geron’s Financial PerformanceExploring Geron’s Financial Performance
finance.yahoo.com - March 21 at 5:38 PM
A Close Look at Geron’s ImetelstatA Close Look at Geron’s Imetelstat
finance.yahoo.com - March 21 at 5:38 PM
Why Geron Corporation Stock Is Up Big Again TodayWhy Geron Corporation Stock Is Up Big Again Today
finance.yahoo.com - March 21 at 5:38 PM
Geron to Present at the Needham Healthcare ConferenceGeron to Present at the Needham Healthcare Conference
finance.yahoo.com - March 21 at 8:48 AM
Health Care Sector Update for 03/19/2018: CDTX,MDWD,GERN,REGN - NasdaqHealth Care Sector Update for 03/19/2018: CDTX,MDWD,GERN,REGN - Nasdaq
www.nasdaq.com - March 20 at 8:28 AM
Edited Transcript of GERN earnings conference call or presentation 19-Mar-18 12:30pm GMTEdited Transcript of GERN earnings conference call or presentation 19-Mar-18 12:30pm GMT
finance.yahoo.com - March 20 at 8:28 AM
Stifel Nicolaus Analysts Give Geron (GERN) a $4.00 Price TargetStifel Nicolaus Analysts Give Geron (GERN) a $4.00 Price Target
www.americanbankingnews.com - March 19 at 5:34 PM
Geron (GERN) Q4 2017 Earnings Conference Call TranscriptGeron (GERN) Q4 2017 Earnings Conference Call Transcript
finance.yahoo.com - March 19 at 5:18 PM

SEC Filings

Geron (NASDAQ:GERN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Geron (NASDAQ:GERN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Geron (NASDAQ GERN) Stock Chart for Tuesday, April, 24, 2018

Loading chart…

This page was last updated on 4/24/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.